Medicenna Therapeutics (TSE:MDNA) Stock Price Down 18.2% – Here’s Why

Medicenna Therapeutics Corp. (TSE:MDNA)’s stock price traded down 18.2% during mid-day trading on Thursday . The company traded as low as C$0.51 and last traded at C$0.54. 193,189 shares changed hands during mid-day trading, an increase of 80% from the average session volume of 107,333 shares. The stock had previously closed at C$0.66.

Medicenna Therapeutics Stock Down 3.6%

The business’s 50 day moving average is C$0.66 and its 200-day moving average is C$0.96. The company has a debt-to-equity ratio of 3.30, a quick ratio of 4.65 and a current ratio of 2.68. The firm has a market capitalization of C$45.05 million, a price-to-earnings ratio of -3.60 and a beta of 2.90.

Medicenna Therapeutics (TSE:MDNA) last issued its quarterly earnings results on Thursday, April 30th. The company reported C($0.06) earnings per share for the quarter. Medicenna Therapeutics had a negative net margin of 533,640.00% and a negative return on equity of 103.51%. Equities analysts anticipate that Medicenna Therapeutics Corp. will post -0.37 EPS for the current fiscal year.

Medicenna Therapeutics Company Profile

Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment. The have the potential to purge the tumor and un-blind the immune system to cancer thereby altering the treatment paradigm for a large majority of cancer patients.